Skip to main content
Terug
ABVX logo

Abivax S.A.

Datakwaliteit: 100%
ABVX
NASDAQ Healthcare Biotechnology
€ 110,17
▼ € 5,25 (-4,55%)
Marktkapitalisatie: 7,22B
Ook genoteerd als AAVXF OTC
Dagbereik
€ 109,08 € 116,92
52-Weeksbereik
€ 4,77 € 148,83
Volume
1.361.749
50D / 200D Gem.
€ 119,11 / € 87,46
Vorige Slotkoers
€ 115,42

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E -41,0 0,3
P/B 178,0 2,9
ROE % -149,0 3,7
Net Margin % -1633,1 3,8
Rev Growth 5Y % 261,8 10,0
D/E 2,4 0,2

Koersdoel Analisten

Hold
€ 142,50 +29.3%
Low: € 110,00 High: € 176,00
Forward WPA
-€ 3,07
Omzet Sch.
3,8 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 4,96
€ 3,05 – € 6,87
1,5 B 1
FY2029 € 5,35
€ 3,29 – € 7,41
1,2 B 1
FY2028 € 0,71
€ 0,31 – € 1,11
570 M 2

Belangrijkste Punten

Revenue grew 261,78% annually over 5 years — strong growth
Debt/Equity of 2,40 — high leverage
Negative free cash flow of -154,72M
PEG of 0,14 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 128,24%
Capital efficient — spends only 5,96% of revenue on capex

Groei

Revenue Growth (5Y)
261,78%
Revenue (1Y)133,54%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-148,98%
ROIC-94,05%
Net Margin-1633,08%
Op. Margin-1602,89%

Veiligheid

Debt / Equity
2,40
Current Ratio1,84
Interest Coverage-41,33

Waardering

P/E Ratio
-40,99
P/B Ratio177,99
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 133,54% Revenue Growth (3Y) 53,45%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 261,78% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 10,79M Net Income (TTM) -176,24M
ROE -148,98% ROA -85,88%
Gross Margin 100,00% Operating Margin -1602,89%
Net Margin -1633,08% Free Cash Flow (TTM) -154,72M
ROIC -94,05% FCF Growth (3Y) N/A
Safety
Debt / Equity 2,40 Current Ratio 1,84
Interest Coverage -41,33 Dividend Yield 0,00%
Valuation
P/E Ratio -40,99 P/B Ratio 177,99
P/S Ratio 669,35 PEG Ratio 0,14
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 7,22B Enterprise Value 7,18B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 10,79M 4,62M 4,58M 37.000,0 63.000,0
Net Income -176,24M -147,74M -60,74M -42,45M -37,55M
EPS (Diluted) -2,80 -3,43 -3,18 -2,75 -2,62
Gross Profit 10,79M 4,57M 4,47M -119.000,0 -33,77M
Operating Income -172,98M -127,38M -64,84M -41,40M -38,01M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 205,23M 327,06M 75,54M 109,23M 71,30M
Total Liabilities 164,64M 131,05M 68,36M 83,30M 53,40M
Shareholders' Equity 40,58M 196,01M 7,19M 25,93M 17,90M
Total Debt 97,36M 58,04M 39,16M 51,65M 33,99M
Cash & Equivalents 144,22M 251,94M 26,95M 60,70M 29,30M
Current Assets 170,67M 285,97M 36,18M 75,21M 37,67M
Current Liabilities 92,83M 88,12M 51,46M 32,26M 19,41M

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Full Throttle
#5 of 146
77

Recente Activiteit

Ingestapt Full Throttle
Mar 24, 2026